$精密科学(EXAS)$ March 24, 2014
13:34 EDT EXAS Questions for FDA panel on Cologuard not surprising, says Roth Capital
Roth Capital does not view any of the questions being asked by the FDA to the panel meeting to assess Exact Sciences' Cologuard as surprising. The firm continues to think Cologuard is positioned to receive a positive recommendation and has a Buy rating on Exact shares. 同意此看法，会通过FDA，The panel 会增加一些建议而已